PepGen Q2 Net Loss Narrows to $17.8M; Cash $117.2M

PepGen Inc. reported a reduced net loss of $17.8 million for the second quarter of 2026, an improvement from $23.1 million in the same period last year. For the six months ended June 30, 2026, the net loss also decreased to $35.6 million from $53.3 million year-over-year. The clinical-stage biotechnology company ended the quarter with $117.2 million in cash, cash equivalents, and marketable securities, which it believes is sufficient to fund operations for at least the next 12 months. The company continues to incur significant operating losses and expects to raise additional funding.